Is confidence in the AstraZeneca vaccine falling after the stop and subsequent resumption of the vaccination campaign in the European Union? It may be so, but as always the answer comes from science. According to the long-awaited results from a trial that comes from the United States, the Anglo-Swedish vaccine is safe. The results are now available and confirm that it is a drug that is not only safe but also highly effective.
*** Subscribe to the Special Coronavirus Newsletter
These are the results
Meanwhile, the numbers: 32,000 volunteers participated in the trial, mainly in the United States, Peru and Chile. Well, the results show that the vaccine was 79% effective in stopping the symptomatic Covid disease and 100% in prevent people from becoming seriously ill. As regards, however, one of the aspects that has raised the greatest concern, those of blood clots, the answer is that no problems were found.
The age of the volunteers
About a fifth of the volunteers in this study were over 65, and the vaccine, given in two doses, four weeks apart, provided them with the same protection compared to age groups. younger. The results of this trial should pave the way for regulatory authorities to approve the Oxford-Astrazeneca vaccine in the United States within the next month or two. The lead researcher of the vaccine trial at the University of Oxford, Professor Andrew Pollard, said that ‘these results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results of studies conducted by Oxford. We can expect a strong impact against Covid-19 in all ages and for people of all different backgrounds from the widespread use of the vaccine “.
https://lab.gedidigital.it/gedi-visual/2020/coronavirus-le-vaccinazioni-nel-mondo/
Professor Sarah Gilbert, co-designer of the vaccine, in turn noted: ‘In many different countries and in all age groups, the vaccine provides a high level of protection against Covid-19 and we hope this will lead to a even more widespread use of the vaccine in global attempts to end the pandemic ”. “It’s really important to have the ability to protect people as quickly as possible. This vaccine will save lives, ”added Gilbert.
Continue the data analysis
“AstraZeneca will continue to analyze the efficacy and safety data” emerging from studies on the anti-Covid vaccine developed with the University of Oxford, and is preparing “a primary analysis to be submitted to the US Food and Drug Administration”, the Agency American for the Fda drug, “for the authorization for emergency use in the coming weeks” explains the Anglo-Swedish company. “At the same time – reads a note – the primary analysis will be presented for publication in a peer-reviewed journal”.
The new results “add to the growing evidence that this vaccine is well tolerated and highly effective against Covid-19 at all severity levels and in all age groups – says Mene Pangalos, Executive Vice President BioPharmaceuticals R&D at AstraZeneca – We are confident that this vaccine can play an important role in protecting millions of people around the world from a deadly virus. We are preparing to present these results to the Food and Drug Administration – he confirms – and for the launch of millions of doses across America in the event that the vaccine obtains authorization for emergency use in the United States ».